Objectives. To review bladder specimens referred to our facility for secondary review to determine the frequency and degree of changes in pathological diagnoses, which could affect patient care. Methods. A retrospective review of 246 bladder specimens sent to our pathology department for second opinion pathological review was performed. All consultation specimens were reviewed by a single genitourinary (GU)-subspecialized surgical pathologist. Any changes in the pathological grade, stage, or histological tumor type were noted as well as patient demographic data. Statistical analysis was performed to determine the frequency and type of discrepancies in diagnoses and determine any associations with patient demographic parameters. Results. Secondary pathology consultation of 246 bladder specimens from 233 patients were reviewed and compared with the primary diagnosis. The diagnosis was altered in 91/246 cases (37.0%). The number of cases reviewed per patient and specimen type was not associated with a change in diagnosis (P = .19; P = .1). Of the cases with a change in diagnosis, 8 (8.8%) changed malignancy status, 46 (50.5%) changed stage, 16 (17.6%) changed tumor type (ie, change from urothelial carcinoma to prostate adenocarcinoma), 16 (17.6%) changed histological variant subtype, and 14 (15.4%) changed grade. There was no association noted between age, gender, or race and changes in diagnosis (P = .53; P = .41; P = .70). Conclusions. Secondary pathology review with a GU-subspecialized surgical pathologist can change the stage, grade, or histological subtype on bladder biopsy and tumor resection specimens in more than one-third of cases. Age and gender were not associated with the frequency of change in diagnosis on consultation review.
Introduction
Bladder cancer is the sixth most commonly diagnosed malignancy in the United States, with an estimated 79 000 newly diagnosed cases in 2017, responsible for nearly 27 000 deaths annually. 1 Bladder cancer is also one of the most costly cancers to manage. 2 Appropriate grading and staging of bladder cancer is critical in guiding the patient toward the appropriate treatment algorithms. Noninvasive, low-grade tumors can be managed with active surveillance, whereas tumors invading into the muscularis propria require radical surgery. Current imaging techniques are limited in the precise staging of localized disease. 3 Thereby, appropriate staging of bladder cancer is reliant on the pathological assessment of transurethral bladder and prostatic urethral specimens. Pathological evaluation is also essential in differentiating primary bladder cancer from benign mimickers of tumor, such as nephrogenic adenoma, and other nonurothelial malignancies, such as prostate cancer. Tumor origin, stage, grade, variant histological subtype, and presence of muscularis propria for analysis are important criteria in the proper diagnosis and risk stratification of patients, with significant implications in treatment decision making.
It is well recognized that second opinion pathology consultation may alter the diagnosis in various malignancies, including bladder cancer. [4] [5] [6] [7] [8] [9] Referral of patients to tertiary care centers often provides the opportunity for secondary pathology consultation to be rendered by 1 University of Alabama at Birmingham, AL, USA site-specific or organ-system subspecialized surgical pathologists, which has been shown to improve consistency in diagnoses. [10] [11] [12] The purpose of this study was to review bladder specimens referred to our facility for secondary review to determine the frequency and degree of changes in pathological diagnoses.
Methods
A retrospective review of bladder specimens and prostatic urethral biopsies referred to our institution between January 2014 and March 2017 was performed. All cases were sent in with a finalized diagnosis. The secondary review of pathology was performed only because the patient was referred to our institution for therapy. True consult cases, where the diagnosis was uncertain, were excluded from this study. A single fellowship-trained genitourinary (GU)-subspecialized surgical pathologist (JG) evaluated all specimens and rendered a secondary pathological diagnosis for each case based on the histology provided for review. All cases that had a discrepancy with the outside diagnosis were additionally brought to the departmental consensus conference for group assessment and agreement. The secondary diagnosis was compared to the referring center pathological diagnosis, evaluating for changes in malignancy status, grade, stage, tumor histological classification, presence of muscularis propria, and variant urothelial carcinoma subtypes when applicable. These criteria were assessed as indicated by the current recommendations of the World Health Organization and the International Society of Urological Pathology. 13, 14 Statistical analysis was performed on a per-patient basis to evaluate if age, gender, or race were associated with a change in pathological diagnosis between the report from the referring center and second opinion pathological consultation at our institution. Cases with a change in diagnosis were further classified as having a major change in diagnosis versus a minor change. A case was considered to have a major change if there was a significant impact on the clinical management. A major change in diagnosis was considered in the following situations: pTa tumors with a change in grade (high to low or low to high), change in stage from pT2 to pT1, change in stage from pT1 to pT2, unidentified micropapillary or sarcomatoid features in nonmuscle invasive cases, change in the presence/absence of a small-cell neuroendocrine carcinoma component, pT1 tumors with a change in the presence of muscularis propria, misdiagnosis of urothelial origin (eg, prostatic adenocarcinoma), change in diagnosis from benign to malignant, and change in diagnosis from malignant to benign. Because some cases had multiple changes in diagnosis, all changes were considered on a per-case basis in the determination of overall major versus minor impact on clinical management. Continuous variables were computed as means with SDs and compared using 2-tailed Student's t-tests. Categorical data were expressed as frequency counts and percentages with comparisons conducted using χ 2 analysis, with Fisher exact modifications when appropriate based on observed frequencies. All statistical analyses were performed using the JMP 10 (SAS Institute Inc, Cary, NC) statistical software package.
Results
Slides were reviewed on 246 bladder specimens from 233 patients sent for pathology secondary consultation. Of these, there were 241 (98.0%) transurethral bladder and/or prostatic urethral biopsies, 3 (1.2%) partial cystectomy specimens, and 2 (0.8%) cystoprostatectomy specimens. Seven patients (3.0%) had specimens sent for secondary review from 2 separate procedure dates, and 3 patients (1.3%) had specimens submitted from 3 separate procedure dates. The number of cases submitted per patient was not associated with a change in diagnosis (P = .19; Table 1 ).
Of the 246 cases included in this analysis, the average age at the time of specimen collection was 66.7 ± 11.9 years, ranging from 17 to 93 years. Age was not found to be associated with change in diagnosis on secondary consultation (67.3 ± 12.6 years) as compared with those with agreement in diagnosis (66.3 ± 11.6 years): P = .54. The sex distribution was 172 men (73.8%) and 61 women (26.2%) in the group overall and was not found to be significantly associated with a change in diagnosis: P = .41. The racial distribution was not statistically different when comparing patients who had a change in diagnosis versus those who did not on secondary pathology review (P = .70; Table 1 ).
On secondary pathology review, the diagnosis was altered in 91 of 246 cases (37.0%) examined, which affected 89/233 (38.2%) patients. A major change in diagnosis was seen in 47/246 (19.1%) cases undergoing secondary review. All changes were found to involve either transurethral bladder or prostatic urethra specimens. All partial cystectomy and radical cystectomy specimens in our series had complete agreement for the pathological diagnosis. The type of specimen was not associated with change in diagnosis (P = .1; Table 1 ).
Multiple changes in diagnostic criteria were evaluated in a nonexclusionary manner. Of the 91 cases with changes in diagnosis, 8 (8.8%) changed malignancy status, 46 (50.5%) changed stage, 16 (17.6%) were changed to a different tumor classification (example: change from urothelial carcinoma to prostatic adenocarcinoma), 16 (17.6%) changed histological variant subtype of urothelial carcinoma, 14 (15.4%) changed grade, and 26 (28.6%) had a change in the presence of muscularis propria for evaluation (Table 2) . (continued) 
Discussion
Rendering a correct pathological diagnosis is critical in the management of urothelial carcinoma. There are multiple factors that can cause errors to occur in the pathological interpretation of bladder specimens. Most specimens are fragmented and cauterized, which along with a lack in subspecialization training, can make bladder specimens challenging even for experienced pathologists. Previous studies have shown the benefit of having bladder specimens reviewed, in particular by pathologists specializing in GU pathology. [15] [16] [17] [18] In a study by Luchey et al, 15 1191 transurethral bladder biopsies were reviewed at a Comprehensive Cancer Center that were originally diagnosed at community hospitals. They found a change in diagnosis in 15.3% of cases that would create potential treatment alterations. In a similar study, Lee et al 16 analyzed transurethral bladder tumor specimens that underwent secondary review by GU pathologists at the Cleveland Clinic. They found that 31/116 (26.7%) cases in 2004 differed substantially from the initial report. In our series, we evaluated each case to determine impact on clinical management, with some cases having multiple changes in diagnosis. We found a major change in diagnosis in 47/246 (19.1%) cases undergoing secondary review at our institution. This relatively high proportion is consistent with the current literature and may be a result of the lack of major academic centers that serve the state of Alabama. Community hospitals may be less likely to have subspecialized surgical pathology, which can affect diagnostic accuracy. Our findings continue to support the necessity of secondary pathology review of transurethral bladder resection specimens by a GU pathologist.
In our study, we found a change in stage to be the most common discrepancy, occurring in more than half of all cases with a change in diagnosis. Among cases with a change in stage, the most common issue pathologists faced was distinguishing between noninvasive tumors and lamina propria invasion (pT1). Of the 46 cases with a change in stage, 32.6% had tumors that were called noninvasive at outside institutions but were upstaged to pT1. This was especially noticed in specimens with papillary tumors and little presence of underlying connective tissue. In such cases, superficial invasion was able to be identified in the fibrovascular cores of papillae. Features of invasion include the presence of irregular nests or single cells and a desmoplastic reaction to infiltrating tumor. The presence of paradoxical maturation, where the invasive tumor cells acquire abundant eosinophilic cytoplasm, can also be helpful in identifying superficial invasion.
A similar number of cases (30.4%) with a change in diagnosis were downstaged from pT2 to pT1. Diagnosis of muscularis propria invasion is crucial in the management of patients with bladder cancer. Patients with noninvasive or superficially invasive tumors into the lamina propria are candidates for cystoscopic resection and treatment with intravesical agents. Patients with muscularis propria invasion are recommended to undergo radical cystectomy. Thus, it is critically important to correctly identify the depth of invasion. Fragmentation and cautery artifact can make histological evaluation of depth of invasion difficult in some cases. In addition, invasive urothelial carcinoma is destructive, causing a desmoplastic reaction as it infiltrates through the stroma. The spindled cells seen in desmoplastic stroma can be confused for smooth muscle. Invasive carcinoma can also obliterate the large muscle bundles of the detrusor muscle. It is often difficult to distinguish obliterated muscularis propria from hyperplastic muscularis mucosae, which is present in the lamina propria.
Immunohistochemical stain for desmin can be helpful in these challenging cases. Desmin will highlight smooth muscle bundles within the resection specimen. This can allow the pathologist to distinguish smooth muscle from the fibrosis associated with desmoplasia. Large amounts of smooth muscle would favor a diagnosis of muscularis propria over muscularis mucosae.
We also found that 18% of cases with a change in diagnosis had a histological variant of urothelial carcinoma that went unidentified. Urothelial carcinoma with histological variants, such as micropapillary or sarcomatoid features, has been associated with a poor clinical course. 19, 20 Micropapillary or sarcomatoid features can lead to a more aggressive surgical approach or change in chemotherapeutic recommendations. As such, we considered a misdiagnosis of micropapillary or sarcomatoid histology in non-muscle invasive cases to be a major change in diagnosis. Micropapillary urothelial carcinoma was the most commonly undiagnosed variant on primary pathology review. The diagnosis of micropapillary features is known to have interobserver variability and may reflect subjective interpretation. For example, invasive urothelial carcinoma can often have retraction artifact, which can be confused for either lymphovascular invasion or mircopapillary features. An immunohistochemical stain for vascular channels, such as CD31 or ERG, can be used to confirm lymphovascular invasion. At our institution, the diagnosis of micropapillary features requires the presence of multiple small nests of similar size contained within a single lacuna. This helps distinguish micropapillary morphology from retraction artifact, which will typically show a single nest surrounded by a clear space. More rare features such as nested, sarcomatoid, and lymphoepithelioma-like urothelial carcinoma were also missed. This is not unexpected because these patterns may rarely be seen in a community setting as opposed to an academic center with a large volume of GU surgical specimens. Some non-fellowship-trained pathologists may also have a more difficult time recognizing these more rare findings because of a lack of exposure during training.
We identified a discrepancy in the primary tumor classification in 18% of cases with a change in diagnosis. A common scenario that we encountered was prostatic adenocarcinoma misdiagnosed as urothelial carcinoma. This is a critical mistake given the marked difference in clinical management between the 2 cancers. Prostatic adenocarcinomas that are poorly differentiated can easily be mistaken for urothelial carcinoma. In fact, histological features such as nuclear pleomorphism and papillary structures that are associated with urothelial carcinoma can occur in some prostatic adenocarcinomas. 21 Poorly differentiated tumors of the bladder should be stained with immunohistochemical markers to help distinguish between these 2 entities. 22 Prostatic origin can be confirmed with immunohistochemical markers such as NKX3.1, PSA, and p501S. Urothelial origin can be confirmed with p63, high-molecular-weight cytokeratin, and GATA3. It should be noted that CK7 and CK20 are not useful in these cases because poorly differentiated prostatic carcinoma can show CK7 and CK20 positivity.
The histological grading of urothelial tumors was also found to be an area of difficulty, seen in 15% of cases with a change in diagnosis. We noted that some pathologists were still using the 3-tiered grading system that includes an intermediate grade. This system should no longer be used in the grading of urothelial carcinoma. Per the 2016 World Health Organization classification, papillary urothelial tumors include urothelial papilloma, papillary urothelial neoplasm of uncertain malignant potential (PUNLMP), low-grade papillary urothelial carcinoma, and high-grade papillary urothelial carcinoma. 13, 14 Urothelial papilloma is a benign tumor characterized by delicate fibrovascular cores and normal appearing urothelium, both in terms of cytology and thickness. PUNLMP should have fibrovascular cores lined by thickened urothelium with no cytological atypia. Mitotic activity should be absent. Polarity and nuclear pleomorphism are the best features to distinguish between low-grade and high-grade papillary urothelial carcinoma. Low-grade papillary urothelial carcinoma has mild cytological atypia/pleomorphism and better maintained polarity. High-grade urothelial carcinoma has moderate to marked cytological atypia/pleomorphism and loss of polarity and is associated with increased mitotic activity. Distinguishing between low-and high-grade lesions significantly affects clinical management. Low-grade papillary urothelial carcinoma is managed with cystoscopic resection and surveillance, whereas high-grade papillary urothelial carcinoma is treated with adjuvant intravesical BCG instillation treatments, which is not without side effects. In addition, high-grade lesions have an increased risk of recurrence and progression.
All GU consult cases at our institution are reviewed by fellowship-trained, GU-subspecialized pathologists with additional consensus review on cases that have a differing diagnosis from the outside institution. There has been literature published highlighting the benefit of subspecialization training and the importance of a second opinion in patients with urological malignancies. [15] [16] [17] [18] For this reason, a secondary pathology opinion is required by many institutions prior to a patient undergoing surgery. Our study similarly shows the importance of reevaluating the pathology of patients referred from outside institutions and having that evaluation performed by a pathologist with subspecialty expertise.
Conclusion
Secondary pathology review of bladder specimens by a GU subspecialized surgical pathologist can show a major change in diagnosis in almost 20% of cases. Age, gender, and race were not associated with a change of diagnosis on secondary pathology review.
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